We are live on ! Find out more
SYRE icon

Spyre Therapeutics
SYRE

87 hedge funds and large institutions have $352M invested in Spyre Therapeutics in 2020 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 43 increasing their positions, 13 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

267% more capital invested

Capital invested by funds: $95.8M → $352M (+$256M)

231% more repeat investments, than reductions

Existing positions increased: 43 | Existing positions reduced: 13

213% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 8

50% more funds holding in top 10

Funds holding in top 10: 2 → 3 (+1)

24% more funds holding

Funds holding: 70 → 87 (+17)

0.58% more ownership

Funds ownership: 2.83% → 3.41% (+0.58%)

Holders
87
Holders Change
+17
Holders Change %
+24.29%
% of All Funds
1.78%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.06%
New
25
Increased
43
Reduced
13
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BCLSI
Bain Capital Life Sciences Investors
Massachusetts
+$20.6M
2
BBA
Baker Bros. Advisors
New York
+$20.3M
3
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$10.8M
4
BlackRock
BlackRock
New York
+$9.96M
5
O
OrbiMed
New York
+$8.76M

Top Sellers

Rank Fund Capital Flow
1
SCM
Soleus Capital Management
Connecticut
-$1.27M
2
BCM
Bridgeway Capital Management
Texas
-$534K
3
RWM
Ritholtz Wealth Management
New York
-$381K
4
Renaissance Technologies
Renaissance Technologies
New York
-$347K
5
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO)
Texas
-$327K
Name Holding Trade Value Shares
Change 		Change in
Stake
A
26
Abingworth
United Kingdom
$2.22M – – –
SCM
27
Sio Capital Management
New York
$1.95M +$1.61M +8,444 New
N
28
Nuveen
North Carolina
$1.93M +$913K +4,792 +135%
Millennium Management
29
Millennium Management
New York
$1.7M +$1.29M +6,781 +1,217%
RWM
30
Ritholtz Wealth Management
New York
$1.61M -$381K -2,000 -22%
Bank of New York Mellon
31
Bank of New York Mellon
New York
$1.3M +$348K +1,825 +48%
SCM
32
Suvretta Capital Management
New York
$1.09M +$898K +4,717 New
Charles Schwab
33
Charles Schwab
California
$1.01M +$368K +1,932 +80%
California Public Employees Retirement System
34
California Public Employees Retirement System
California
$860K +$396K +2,080 +127%
D.E. Shaw & Co
35
D.E. Shaw & Co
New York
$860K +$501K +2,628 +241%
Two Sigma Investments
36
Two Sigma Investments
New York
$762K +$358K +1,880 +133%
Russell Investments Group
37
Russell Investments Group
United Kingdom
$603K +$21.7K +114 +5%
Deutsche Bank
38
Deutsche Bank
Germany
$588K +$95.4K +501 +25%
California State Teachers Retirement System (CalSTRS)
39
California State Teachers Retirement System (CalSTRS)
California
$586K +$172K +903 +55%
Invesco
40
Invesco
Georgia
$580K +$477K +2,507 New
William Blair & Company
41
William Blair & Company
Illinois
$483K +$190K +1,000 +92%
SCA
42
Snowden Capital Advisors
New York
$477K – – –
RhumbLine Advisers
43
RhumbLine Advisers
Massachusetts
$477K +$103K +543 +36%
FSA
44
Franklin Street Advisors
North Carolina
$463K +$114K +600 +43%
UBS Group
45
UBS Group
Switzerland
$403K -$3.43K -18 -1%
Two Sigma Advisers
46
Two Sigma Advisers
New York
$395K +$73.1K +384 +29%
Squarepoint
47
Squarepoint
New York
$359K +$114K +601 +63%
New York State Common Retirement Fund
48
New York State Common Retirement Fund
New York
$355K +$149K +780 +103%
Qube Research & Technologies (QRT)
49
Qube Research & Technologies (QRT)
United Kingdom
$334K +$275K +1,444 New
Wells Fargo
50
Wells Fargo
California
$313K -$264K -1,385 -51%
1
2
3 4

SYRE Hedge Fund Activity: Q2 2020 in Review

87 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in Spyre Therapeutics (SYRE) for Q2 2020, worth a combined $352M — up 267% from $95.8M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new SYRE positions and 8 closed out — a net gain of 17 holders — while 43 added to existing stakes and 13 trimmed.

The largest buyer was Bain Capital Life Sciences Investors, opening a new position worth an estimated $20.6M. The largest seller was Soleus Capital Management, cutting an estimated $1.27M.

  • 87 institutional investors held Spyre Therapeutics (SYRE) as of Q2 2020, up from 70 in Q1 2020.
  • Funds reported $352M of Spyre Therapeutics stock for Q2 2020, up 267% quarter-over-quarter.
  • 25 funds opened new Spyre Therapeutics positions in Q2 2020 and 8 closed out, a net change of +17 holders.
  • The largest Spyre Therapeutics buyer in Q2 2020 was Bain Capital Life Sciences Investors, an estimated $20.6M added.
  • The largest Spyre Therapeutics seller in Q2 2020 was Soleus Capital Management, an estimated $1.27M sold.

Based on aggregated 13F filings for Q2 2020.